End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
788,000 KRW | +0.51% | +0.13% | +3.68% |
May. 06 | Samsung Group Firms Set to Invest in US-based Latus Bio | MT |
Apr. 25 | Samsung Bioepis Granted Approval to Market Autoimmune Treatment in Europe | MT |
Sales 2024 * | 4,266B 3.16B | Sales 2025 * | 4,931B 3.65B | Capitalization | 56,085B 41.5B |
---|---|---|---|---|---|
Net income 2024 * | 975B 722M | Net income 2025 * | 1,178B 872M | EV / Sales 2024 * | 12.7 x |
Net cash position 2024 * | 1,742B 1.29B | Net cash position 2025 * | 2,750B 2.03B | EV / Sales 2025 * | 10.8 x |
P/E ratio 2024 * |
57.5
x | P/E ratio 2025 * |
48.8
x | Employees | 4,284 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 25.25% |
1 day | +0.51% | ||
1 week | +0.13% | ||
Current month | +0.90% | ||
1 month | +1.55% | ||
3 months | -4.83% | ||
6 months | +8.99% | ||
Current year | +3.68% |
Managers | Title | Age | Since |
---|---|---|---|
John Chongbo Rim
CEO | Chief Executive Officer | 62 | 17-12-31 |
Doyoung Heo
DFI | Director of Finance/CFO | - | - |
Tae-Han Kim
CHM | Chairman | 66 | 11-04-20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chang-Woo Lee
BRD | Director/Board Member | 70 | - |
Tae-Han Kim
CHM | Chairman | 66 | 11-04-20 |
Seok-Woo Jung
BRD | Director/Board Member | 62 | - |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
4.63% | 2 M€ | -14.14% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 788,000 | +0.51% | 45,694 |
24-05-16 | 784,000 | +0.38% | 65,778 |
24-05-14 | 781,000 | 0.00% | 28,625 |
24-05-13 | 781,000 | -0.76% | 35,239 |
24-05-10 | 787,000 | +0.77% | 65,984 |
End-of-day quote Korea S.E., May 16, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.68% | 41.45B | |
-2.32% | 90.45B | |
-10.90% | 33.57B | |
-19.56% | 14.73B | |
-9.06% | 12.82B | |
-11.34% | 11.7B | |
-43.53% | 11.44B | |
+3.75% | 8.79B | |
-6.32% | 8.35B | |
-9.24% | 6.86B |
- Stock Market
- Equities
- A207940 Stock